Psoriasis
New insights into psoriasis comorbidity
Long-term psoriasis treatment with bimekizumab results in maintained efficacy
Novel developments in topical psoriasis therapy
JAK inhibitors: A risk assessment
Intestinal microbe-preparation: Modest activity but safe for mild psoriasis
Potential biomarker discovered for treatment response to ustekinumab
TNF inhibitor for immune-mediated inflammatory disease doubles the risk of paradoxical psoriasis
Secukinumab also tolerable in paediatric psoriasis patients
High treatment success with ixekizumab in patients with psoriasis and diabetes
The Yin and Yang of opposing vectors: an explanation for side effects of biologics
DLQI scores underestimated during lockdowns?
TNF blockers likely beneficial for psoriatic patients with COVID-19
Patients on immunomodulators need 2 COVID-19 vaccinations before seroconversion
IL-36 gene expression in GPP lesions reduced by spesolimab
Inhibition of heat shock protein: A novel way to treat psoriasis?
Guselkumab shows highest drug survival among systemic treatments
Risankizumab superior to ustekinumab in skin histopathology scores
Tapering biologics: No alarming signs of increased anti-drug antibodies
Intermediate monocytes are possible predictors of response to secukinumab
Gut microbiota of psoriasis patients: less diverse and reduced functionality
Psoriasis associated with a higher cancer risk
Comorbidity and clinical features of psoriasis vary according to HLA-C*06:02 status
Psoriasis patients with cardiovascular comorbidity characterised by high systemic inflammation
HLA-C*06:02-positive patients on ustekinumab show higher drug survival in a real-world scenario
Protective factors identified against anti-drug antibody formation to adalimumab in psoriasis
Dermatologists and psoriasis patients call for specialized care to prevent heart disease
One week enough to clear pustular psoriasis in half of patients after experimental infusion
Experimental cream improves plaque psoriasis but can spark local side effects, headaches
Psoriasis tied to small increase in risk of venous thromboembolism, peripheral vascular disease
Comparing routes of administration of methotrexate in psoriasis patients
TYK2 inhibitor deucravacitinib shows impressive long-term response in psoriasis
Tapinarof cream for psoriasis leads to high clearance rates and remittive effect
Existing and upcoming small molecules in psoriasis
Treating psoriasis during pregnancies
A patient-related approach to freedom of disease
Ixekizumab superior to secukinumab in real-world psoriasis study
Nail psoriasis: An important target to be treated
Grand debate: Is psoriasis a systemic or skin-only disease?
EADV 2021 Highlights Podcast
Live varicella-zoster vaccine safe, effective with TNF inhibitors
Could steroid treatment speed recovery from infliximab-induced liver injury?
PsoBarrier EU: Large survey evaluating quality of care in Europe
Bridging the gap between patients and access to psoriasis specialists
Psoriasis and PsA in transgender adults on hormone therapy
Psoriasis: New disease severity classification
Psoriasis registries yield important data about COVID-19
COVID-19 affects patients and care
Vaccination feasible in people with psoriatic disease
Low COVID-19 risk for patients with psoriasis on biologic treatment
Psoriasis: Disrupted gut-skin axis
Psoriasis associated with increased duodenum inflammation
Whole-exome sequencing to study the underlying pathogenesis of psoriasis
Potential role of inflammation in cardiovascular comorbidity
Psoriasis: New treatments and current pipeline
Rapid pustule and skin clearance with IL-36 receptor inhibitor spesolimab
Selective TYK2 inhibitor effective in moderate-to-severe plaque psoriasis
Certain biologics may boost serious infection risk in patients with psoriasis
Methotrexate use tied to weakened antibody response after first Pfizer-BioNTech vaccine shot
Psoriasis and hidradenitis suppurativa during COVID-19: keep calm and carry on
Psoriasis: The treatment armamentarium continues to grow
Psoriasis management in times of COVID-19: the knowledge is growing steadily
Lower burden of high-risk atherosclerotic plaques in psoriasis patients treated with biologics
Convincingly low levels of infections with long-term tildrakizumab
Small molecule effective in moderate-to-severe psoriasis
Bimekizumab superior to secukinumab in psoriasis
Novel easy-to-use foam formulation clears scalp psoriasis in one-third of patients
New psoriasis injection bests secukinumab, adalimumab in separate tests
Switch from adalimumab to its biosimilar not tied to drug retention in psoriasis patients
Risankizumab long-term risk-benefit profile for moderate to severe psoriasis
Real-world data on brodalumab affirms efficacy and fast onset of action
Bimekizumab in psoriasis: Up-and-coming
Biologic psoriasis treatment and COVID-19 risk: Contradictory results
Selective IL-23 blocker shows potential in psoriasis treatment
Promising results with nanobody treatment in psoriasis
Efficacious non-steroidal topical for psoriasis
Risankizumab improves patient-reported outcomes in moderate to severe psoriasis
Improvement of coronary-artery-plaque lipid-rich necrotic core seen with biologic therapy of psoriasis
Selective IL-23 blocker safe in elderly psoriasis patients
Psoriasis therapy for children and pregnancies
Biologic psoriasis treatment to lower cardiovascular risk?
A new topical PDE-4 inhibitor effective in psoriasis
IL-17A and IL-17F blockade remarkably effective in psoriasis
Novel IL-23 blocker risankizumab highly effective and tolerable in psoriasis
Tape stripping – a painless way to distinguish AD and psoriasis?
Can gene expression help to pick the right biologic to treat psoriasis in cancer patients?
Lowest risk of infection after therapy with an IL-12/IL-23 blocker
Psoriasis onset determines sequence of symptoms
IL-17A blocker effective in paediatric psoriasis patients
Biologics: increasingly used in paediatric dermatology
Comorbidities more common in chronic urticaria, psoriasis, and AD
IL-17 blocker: effective and safe in patients with comorbidities
Reduced sleep quality in dermatoses influenced by itch and pain
ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker
Relationship psoriasis and NAFLD: new data on the hepato-dermal axis
Novel selective IL-23 blocker equally effective in patients with metabolic syndrome
Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints
Certolizumab pegol efficacious for head and neck psoriasis
No hint of teratogenicity through ixekizumab
Novel selective IL-23 blocker highly effective over 2 years
Favourable safety profile of long-term use of ixekizumab
Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies
Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients
Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis?
Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis
ABP501 biosimilar for adalimumab: What you need to know
Reduction in coronary artery disease in psoriasis patients treated with biologic therapies, possible implications for atopic dermatitis
Atopic dermatitis and psoriasis: on a spectrum?
Small molecules, apremilast, and TYK2
Secukinumab maintains improvements in psoriasis through 5 years of treatment
Dual IL-17A and IL-17F blocker leads to unprecedented response rates in psoriasis
Serlopitant reduces pruritus associated with psoriasis
Psoriasis and Biologics: The Beat Goes On
